Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Jun 1;5(6):631-641.
doi: 10.1001/jamacardio.2020.0239.

Long-term Outcomes in Patients With Severely Reduced Left Ventricular Ejection Fraction Undergoing Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting

Affiliations
Multicenter Study

Long-term Outcomes in Patients With Severely Reduced Left Ventricular Ejection Fraction Undergoing Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting

Louise Y Sun et al. JAMA Cardiol. .

Erratum in

  • Errors in Table 2.
    [No authors listed] [No authors listed] JAMA Cardiol. 2020 Jun 1;5(6):732. doi: 10.1001/jamacardio.2020.1655. JAMA Cardiol. 2020. PMID: 32401261 Free PMC article. No abstract available.

Abstract

Importance: Data are lacking on the outcomes of patients with severely reduced left ventricular ejection fraction (LVEF) who undergo revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

Objective: To compare the long-term outcomes in patients undergoing revascularization by PCI or CABG.

Design, setting, and participants: This retrospective cohort study performed in Ontario, Canada, from October 1, 2008, and December 31, 2016, included data from Ontario residents between 40 and 84 years of age with LVEFs less than 35% and left anterior descending (LAD), left main, or multivessel coronary artery disease (with or without LAD involvement) who underwent PCI or CABG. Exclusion criteria were concomitant procedures, previous CABG, metastatic cancer, dialysis, CABG and PCI on the same day, and emergency revascularization within 24 hours of a myocardial infarction (MI). Data analysis was performed from June 2, 2018, to December 28, 2018.

Exposures: Revascularization by PCI or CABG.

Main outcomes and measures: The primary outcome was all-cause mortality. Secondary outcomes were death from cardiovascular disease, major adverse cardiovascular events (MACE; defined as stroke, subsequent revascularization, and hospitalization for MI or heart failure), and each of the individual MACE.

Results: A total of 12 113 patients (mean [SD] age, 64.8 (11.0) years for the PCI group and 65.6 [9.7] years for the CABG group; 5084 (72.5%) male for the PCI group and 4229 (82.9%) male for the PCI group) were propensity score matched on 30 baseline characteristics: 2397 patients undergoing PCI and 2397 patients undergoing CABG. The median follow-up was 5.2 years (interquartile range, 5.0-5.3). Patients who received PCI had significantly higher rates of mortality (hazard ratio [HR], 1.6; 95% CI, 1.3-1.7), death from cardiovascular disease (HR 1.4, 95% CI, 1.1-1.6), MACE (HR, 2.0; 95% CI, 1.9-2.2), subsequent revascularization (HR, 3.7; 95% CI, 3.2-4.3), and hospitalization for MI (HR, 3.2; 95% CI, 2.6-3.8) and heart failure (HR, 1.5; 95% CI, 1.3-1.6) compared with matched patients who underwent CABG.

Conclusions and relevance: In this study, higher rates of mortality and MACE were seen in patients who received PCI compared with those who underwent CABG. The findings may provide insight to physicians who are involved in decision-making for these patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Estimated Long-term Survival After Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Grafting (CABG)
Figure 2.
Figure 2.. Postprocedure Incidences of Study End Points Among Patients Who Underwent Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)

Comment in

References

    1. Gheorghiade M, Sopko G, De Luca L, et al. . Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114(11):1202-1213. doi:10.1161/CIRCULATIONAHA.106.623199 - DOI - PubMed
    1. Bourassa MG, Gurné O, Bangdiwala SI, et al. ; Studies of Left Ventricular Dysfunction (SOLVD) Investigators . Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(4)(suppl A):14A-19A. doi:10.1016/0735-1097(93)90456-B - DOI - PubMed
    1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-1146. doi:10.1136/hrt.2003.025270 - DOI - PMC - PubMed
    1. McMurray JJ, Packer M, Desai AS, et al. ; PARADIGM-HF Investigators and Committees . Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077 - DOI - PubMed
    1. Briceno N, Schuster A, Lumley M, Perera D. Ischaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation. Heart. 2016;102(5):397-406. doi:10.1136/heartjnl-2015-308037 - DOI - PubMed

Publication types

MeSH terms